[Pilot study on the effects of an antiparkinson anticholinergic agent during depressive conditions].
This pilot stuyd was made in order to search for the efficiency of an anticholinergic antiparkinsonian drug, orphenadrine, at high doses (300 to 500 mg/day, orally) in 10 depressed patients. This efficiency seems to be clear and appears quickly: with melancolic patients in particular, we observed 4 very good results in less than 5 days. Nevertheless, besides peripheral anticholinergic side-effects a transitory but very marked spatio-temporal disorganization, with increase of locomotor-activity and sometimes hallucinations, was observed in most patients. Nevertheless, it seems that this therapeutic should be carried on whenever other antidepressant therapeutics failed.
D000328:Adult; D000368:Aged; D003072:Cognition Disorders / Q000139:chemically induced; D003863:Depression / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009966:Orphenadrine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced; D013950:Thymus Gland / Q000187:drug effects
D009966:Orphenadrine
Etude pilote des effets d'un antiparkinsonien anticholinergique au cours d'états dépressifs